Isomorphic Labs Raises $5 Billion Series C for AI Drug Design
Isomorphic Labs raised $5 billion in an oversubscribed Series C led by Greenoaks and Sequoia to scale its IsoDDE AI drug-design engine and move oncology and immunology candidates toward clinical trials.
By Daniel Okafor
4 min read
What's News
- Isomorphic Labs raised $5 billion in an oversubscribed Series C co-led by Greenoaks and Sequoia Capital.
- Alphabet, Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all invested.
- The company's oncology and immunology programs remain preclinical, with no disclosed clinical-trial timeline.
- Founded in 2021, the London-based firm is led by CEO Sir Demis Hassabis and President Max Jaderberg.
Isomorphic Labs has raised $5 billion in an oversubscribed Series C to scale its AI drug-design platform and push preclinical candidates toward human trials. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz joined as a new investor alongside several others, and Alphabet made an additional significant investment.
All existing investors participated, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
The London-based company, founded in 2021, operates as an Alphabet-backed business with capital from external institutional investors. Founder and CEO Sir Demis Hassabis leads the company with President Max Jaderberg. Beyond London, it runs offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
What will the money fund?
The company laid out four uses for the capital:
- Developing additional foundational AI models
- Expanding its drug pipeline
- Building translational and clinical development capabilities
- Establishing global infrastructure for AI-led bioengineering
A portion of the proceeds will pay for global computing, research, and development infrastructure. AI drug design demands large amounts of computing capacity, specialized scientific data, laboratory validation, and teams spanning machine learning, chemistry, biology, pharmacology, and clinical development. Isomorphic plans to integrate those functions through an AI-first development model and will keep hiring researchers and drug-development professionals.
How does the IsoDDE engine work?
Isomorphic Labs has built a proprietary drug-design system called IsoDDE. The platform combines foundational simulation models that work across multiple therapeutic areas and types of medicines. It helps researchers explore large chemical spaces, design molecules, and optimize characteristics relevant to potential drugs.
Drug design forces trade-offs. A molecule may need to hit a specific biological target while staying stable, reaching the intended tissue, avoiding harmful interactions, and remaining practical to manufacture and administer. IsoDDE models several of these considerations at once, so Isomorphic's scientists can refine candidates before and during laboratory testing.
The platform also runs proprietary AI agents that reason across complex biological systems. Isomorphic uses these tools to investigate disease mechanisms and identify paths to new treatments. The company says its simulation models are moving predictions closer to experimental accuracy. Those claims have not been independently validated through approved medicines, and every therapeutic program remains in preclinical development.
Where does the pipeline stand?
Isomorphic is building a multi-modality pipeline across therapeutic approaches and disease areas. Internal programs currently target oncology and immunology. The company is also advancing candidates through collaborations with external partners.
Isomorphic said these programs have produced positive preclinical results and are preparing to move toward clinical development. The caveat is structural. Preclinical results come from laboratory and animal studies, and compounds that perform well at that stage still face scientific, regulatory, manufacturing, and clinical risks.
The new funding will support the infrastructure needed to enter human trials: translational research, manufacturing preparation, regulatory work, and the design and operation of clinical development programs. Isomorphic has not disclosed which internal candidate will enter the clinic first, nor a specific trial timeline.
What do the leaders say?
Hassabis framed the round around the company's founding thesis. "When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," he said. "Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
Jaderberg pointed to the pace of iteration. "Every week we are making repeatable scientific advancements enabled by our models," he said. "These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery." He added that teams combining machine learning researchers with drug hunters are "routinely solving complex biological problems that have stalled traditional research for decades."
Neil Mehta, founder and managing partner of Greenoaks, called drug development "an optimization challenge of almost infinite scale" and said Isomorphic is building deep learning systems that "predict complex biological behaviors with remarkable accuracy." Konstantine Buhler, partner at Sequoia Capital, said the company is "building foundational technology for the future of medicine."
Can one engine serve many diseases?
Beyond its existing drug-design models, Isomorphic plans to expand into additional areas of biology. It is building foundational models intended to represent biological systems at the molecular level, which it believes could sharpen understanding of disease mechanisms and make it easier to design therapeutics with targeted properties.
The company is also developing a partner ecosystem focused on mechanistic disease biology. Those collaborations are expected to supply biological knowledge, experimental data, and therapeutic-development experience.
The long-term objective is a reusable drug-design engine rather than a platform tied to one disease or molecule type. If it works, the same underlying infrastructure would serve multiple therapeutic areas and drug modalities.
The $5 billion round gives Isomorphic substantial resources to fund the expensive transition from preclinical research into human trials. The company will still need to demonstrate that its AI-designed candidates can meet established standards for safety and effectiveness.
Source: pulse2.com
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,300 articles